⚠ BETA — all market data shown (deals, filings, prices, indices) is demo / illustrative, not live trading data. For evaluation only; verify before acting.
June 17, 2026
Investdesk

NSE

Bal Pharma LimitedBALPHARMA

Bal Pharma Limited is a pharmaceutical company engaged in the development, manufacture, marketing, and distribution of generic drugs. It has a strong presence in India.

Key productsGeneric medicines, APIs (Active Pharmaceutical Ingredients)
GeographyIndia, Middle East, Africa
CompetitorsCipla Ltd, Sun Pharma, Dr. Reddy's Laboratories Ltd

AI-generated overview — verify before relying on it.

Net institutional flow

No institutional deals

Institutional buyers

0 in / 0 out

High-impact filings

0 · tilt Neutral

Next corporate action

Dividend - Rs 1.20 Per Share

ex 2025-09-18

Competitive landscape — the read

vs most-traded names · ALL
1M3M6M1Y2YAll
Institutional money is backing ATALREAL hardest (+₹7.2 Cr net). BALPHARMA ranks #4 of 7 on flow (net buying +₹0 Cr).
#CompanyInst. flow ₹CrDealsHi-impactFiling mom.BuzzNews
1ATALREAL+₹7.2 Cr154————
2MOBIKWIK+₹0.1 Cr83————
3QUADFUTURE+₹0 Cr134————
4BALPHARMAThis——————
5MTNL+₹0 Cr2————
6GATECH+₹0 Cr8————
7IRMENERGY−₹2.2 Cr328————

Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.

SWOT

Strengths

  • • Strong presence in India
  • • Wide range of generic medicines
  • • API manufacturing capabilities

Weaknesses

  • • Dependence on Indian market
  • • Competition from global players
  • • Regulatory challenges

Opportunities

  • • Growing demand for affordable medicines
  • • Expansion into new markets (e.g. US, EU)
  • • Diversification of product portfolio

Threats

  • • Increasing competition from generic manufacturers
  • • Patent expiration risks
  • • Stringent regulatory requirements

AI-generated from our data — verify before relying on it.

Timeline — BALPHARMA day by day

1M3M6M1Y2YAll
  1. 2025-09-18ActionDividend - Rs 1.20 Per ShareDividend
  2. 2025-04-04BulkBUY · ₹1.5 CrMUDUPULAVEMULA SURENDRANADHA REDDY
  3. 2025-04-04BulkSELL · ₹1.5 CrMUDUPULAVEMULA SURENDRANADHA REDDY
  4. 2025-04-04BulkBUY · ₹1.6 CrNK SECURITIES RESEARCH PRIVATE LIMITED
  5. 2025-04-04BulkSELL · ₹1.6 CrNK SECURITIES RESEARCH PRIVATE LIMITED
  6. 2025-04-04BulkBUY · ₹1.4 CrPARTH INFIN BROKERS PVT LTD
  7. 2025-04-04BulkSELL · ₹1.4 CrPARTH INFIN BROKERS PVT LTD
  8. 2025-04-04NetDay net +₹0 Cr
  9. 2024-09-17ActionAnnual General Me0etingdividend - Rs 1.2 Per ShareDividend
  10. 2024-08-23BulkSELL · ₹1.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
  11. 2024-08-23BulkBUY · ₹1.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
  12. 2024-08-23NetDay net −₹0 Cr
  13. 2024-08-22BulkSELL · ₹1.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
  14. 2024-08-22BulkBUY · ₹1.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
  15. 2024-08-22NetDay net −₹0 Cr

Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.

Filings that matter

No scored filings for BALPHARMA yet.

Bulk & block deals

1M3M6M1Y2YAll

10 deals · 2024-08-22 → 2025-04-04

DateCounterpartyTypeSideValue
2025-04-04MUDUPULAVEMULA SURENDRANADHA REDDYHNI / otherBUY₹1.5 Cr
2025-04-04MUDUPULAVEMULA SURENDRANADHA REDDYHNI / otherSELL₹1.5 Cr
2025-04-04NK SECURITIES RESEARCH PRIVATE LIMITEDProp / churnBUY₹1.6 Cr
2025-04-04NK SECURITIES RESEARCH PRIVATE LIMITEDProp / churnSELL₹1.6 Cr
2025-04-04PARTH INFIN BROKERS PVT LTDHNI / otherBUY₹1.4 Cr
2025-04-04PARTH INFIN BROKERS PVT LTDHNI / otherSELL₹1.4 Cr
2024-08-23NK SECURITIES RESEARCH PRIVATE LIMITEDProp / churnSELL₹1.2 Cr
2024-08-23NK SECURITIES RESEARCH PRIVATE LIMITEDProp / churnBUY₹1.2 Cr
2024-08-22NK SECURITIES RESEARCH PRIVATE LIMITEDProp / churnSELL₹1.2 Cr
2024-08-22NK SECURITIES RESEARCH PRIVATE LIMITEDProp / churnBUY₹1.2 Cr

10 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.

News & chatter on BALPHARMA

RSS News

0

No recent news.

Google News RSS — links open the source.

Investdesk

0

No articles yet.

Our coverage.

Reddit

0

No Reddit chatter.

r/ posts mentioning the company.

Twitter / X

0

No posts.

Posts mentioning the company.